title: Fluoxetine-induced hepatitis: why is postmarketing surveillance needed?
authors.affiliation: Servei de Farmacologia Clínica, Universitat Autònoma de Barcelona, CSU Vall d'Hebron, Passeig Vall d'Hebron, 119-129, E-08035 Barcelona, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Capellà
authors.forename: M
authors.initials: M
authors.lastname: Bruguera
authors.forename: A
authors.initials: A
authors.lastname: Figueras
authors.forename: J
authors.initials: J
authors.lastname: Laporte
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000410:Alanine Transaminase / Q000097:blood / Q000187:drug effects; D001219:Aspartate Aminotransferases / Q000097:blood / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing / Q000706:statistics & numerical data; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
chemical_list: D000410:Alanine Transaminase; D001219:Aspartate Aminotransferases; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors